These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 9707304)

  • 21. Production of BRO beta-lactamases and resistance to complement in European Moraxella catarrhalis isolates.
    Schmitz FJ; Beeck A; Perdikouli M; Boos M; Mayer S; Scheuring S; Köhrer K; Verhoef J; Fluit AC
    J Clin Microbiol; 2002 Apr; 40(4):1546-8. PubMed ID: 11923393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term trends in susceptibility of Moraxella catarrhalis: a population analysis.
    Walker ES; Neal CL; Laffan E; Kalbfleisch JH; Berk SL; Levy F
    J Antimicrob Chemother; 2000 Feb; 45(2):175-82. PubMed ID: 10660499
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibiotic susceptibilities and drug resistance in Moraxella (Branhamella) catarrhalis.
    Wallace RJ; Nash DR; Steingrube VA
    Am J Med; 1990 May; 88(5A):46S-50S. PubMed ID: 2111092
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract.
    Doern GV
    Am J Med; 1995 Dec; 99(6B):3S-7S. PubMed ID: 8585554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. bro {beta}-lactamase and antibiotic resistances in a global cross-sectional study of Moraxella catarrhalis from children and adults.
    Khan MA; Northwood JB; Levy F; Verhaegh SJ; Farrell DJ; Van Belkum A; Hays JP
    J Antimicrob Chemother; 2010 Jan; 65(1):91-7. PubMed ID: 19889789
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The antibiotic susceptibilities and beta-lactamase production of clinical isolated Branhamella catarrhalis from acute otitis media in children.
    Suzuki K; Baba S; Inagaki M; Kobayashi T
    Auris Nasus Larynx; 1988; 15(2):105-11. PubMed ID: 3144965
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Isolation of Moraxella catarrhalis in patients at King Khalid University Hospital, Riyadh.
    Babay HA
    Saudi Med J; 2000 Sep; 21(9):860-3. PubMed ID: 11376364
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Moraxella catarrhalis as an important etiologic factor in infection of the lower bronchial tree].
    Nowak-Sadzikowska J; Heczko PB
    Pneumonol Alergol Pol; 1994; 62(9-10):530-2. PubMed ID: 7866327
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antimicrobial susceptibility and beta-lactamase production of Moraxella catarrhalis isolates in Taiwan.
    Fung CP; Jang TN; Liu CY; Lau YJ; Liu YC; Chuang YC; Lee N
    J Formos Med Assoc; 1995 Sep; 94(9):548-54. PubMed ID: 8696169
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Moraxella catarrhalis: a review of an important human mucosal pathogen.
    Karalus R; Campagnari A
    Microbes Infect; 2000 Apr; 2(5):547-59. PubMed ID: 10865200
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Serotype distribution and drug resistance of
    Tian HL; Shi W; Zhou HF; Yuan L; Yao KH; Rexiati D; Xu AM
    Zhonghua Er Ke Za Zhi; 2018 Apr; 56(4):279-283. PubMed ID: 29614568
    [No Abstract]   [Full Text] [Related]  

  • 32. [Clinical, diagnostic and therapeutic aspects of Moraxella catarrhalis infections].
    Bourgeois F; Lambert-Zechovsky N; Bingen E
    Pathol Biol (Paris); 1993 Jun; 41(6):555-61. PubMed ID: 8247636
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRO beta-lactamases of Branhamella catarrhalis and Moraxella subgenus Moraxella, including evidence for chromosomal beta-lactamase transfer by conjugation in B. catarrhalis, M. nonliquefaciens, and M. lacunata.
    Wallace RJ; Steingrube VA; Nash DR; Hollis DG; Flanagan C; Brown BA; Labidi A; Weaver RE
    Antimicrob Agents Chemother; 1989 Nov; 33(11):1845-54. PubMed ID: 2514622
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Upper respiratory tract infections. Ecological and therapeutic aspects of beta-lactamase production with special reference to Branhamella catarrhalis.
    Eliasson I; Kamme C
    Drugs; 1986; 31 Suppl 3():116-21. PubMed ID: 3488190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Moraxella catarrhalis: virulence and resistance mechanisms].
    Cullmann W
    Med Klin (Munich); 1997 Mar; 92(3):162-6. PubMed ID: 9173208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapid discrimination between BRO beta-lactamases from clinical isolates of Moraxella catarrhalis using restriction endonuclease analysis.
    du Plessis M
    Diagn Microbiol Infect Dis; 2001 Jan; 39(1):65-7. PubMed ID: 11173194
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Significance, isolation, identification and sensitivity of Branhaemella (moraxella) catarrhalis.
    Hafiz S; Hafiz T; Yazdani I
    J Pak Med Assoc; 1993 Aug; 43(8):153-4. PubMed ID: 8264093
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Susceptibility patterns for amoxicillin/clavulanate tests mimicking the licensed formulations and pharmacokinetic relationships: do the MIC obtained with 2:1 ratio testing accurately reflect activity against beta-lactamase-producing strains of Haemophilus influenzae and Moraxella catarrhalis?
    Pottumarthy S; Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2005 Nov; 53(3):225-31. PubMed ID: 16257168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BRO beta-lactamase alleles, antibiotic resistance and a test of the BRO-1 selective replacement hypothesis in Moraxella catarrhalis.
    Levy F; Walker ES
    J Antimicrob Chemother; 2004 Feb; 53(2):371-4. PubMed ID: 14729761
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular characterization of the beta-lactamases from clinical isolates of Moraxella (Branhamella) catarrhalis obtained from 24 U.S. medical centers during 1994-1995 and 1997-1998.
    Richter SS; Winokur PL; Brueggemann AB; Huynh HK; Rhomberg PR; Wingert EM; Doern GV
    Antimicrob Agents Chemother; 2000 Feb; 44(2):444-6. PubMed ID: 10639381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.